Insight

Ajay Major: Golcadomide and R-CHOP as first line for LBCL by Arnaud Amzallag et al.

Collage photo of Ajay Major and Arnaud Amzallag

Nov 20, 2024, 19:12

Ajay Major: Golcadomide and R-CHOP as first line for LBCL by Arnaud Amzallag et al.

Ajay Major, Assistant Professor of Medicine at the University of Colorado School of Medicine, shared a post on X about a recent abstract by Arnaud Amzallag, Scientific Associate Director at Bristol Myers Squibb:

“Golcadomide (CELMoD) plus R-CHOP first line LBCL.

Randomized 0.2 vs 0.4 mg in dose expansion
1-yr PFS 85% at 0.4 mg (77% at 0.2)
90% EOT MRD- at 0.4 (73% at 0.2)
better EOT MRD- with 0.4 mg across high-risk genetics

GOLSEEK-1 RCT ongoing with 0.4 mg dose.”

“Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL)”

Authors: Arnaud Amzallag, Tara Basavanhally, Jason Westin, Anita Gandhi, Mark Kaplan, et al.

Ajay Major: Golcadomide and R-CHOP as first line for LBCL by Arnaud Amzallag et al.

More posts featuring Ajay Major.

Ajay Major is an Assistant Professor of Medicine at the University of Colorado School of Medicine, specializing in lymphoma and CLL/SLL. He is the Founder and President of Pager Publications, as well as the Founder and Editor-in-Chief of in-House. Additionally, he serves as a Reviewer for the Bellevue Literary Review.

Ajay Major Anita Gandhi Arnaud Amzallag B-cell lymphoma cancer Golcadomide Jason Westin Large B-Cell Lymphoma LBCL Mark Kaplan OncoDaily Oncology R-CHOP Tara Basavanhally

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers